Mitochondrial target of thiazolidinediones

Diabetes Obes Metab. 2014 Nov;16(11):1048-54. doi: 10.1111/dom.12308. Epub 2014 May 22.


Insulin-sensitizing thiazolidinediones exert a pleiotropic pharmacology with therapeutic potential in a number of disease states ranging from metabolic syndrome and diabetes to neurodegeneration and cancer. A growing understanding of their mechanism of action, working from the site of their binding in the mitochondrion, provides insight into the mechanism of action of the insulin sensitizers and the reasons for their pleiotropic pharmacology. This review helps to frame the direction of future work that should be helpful in setting a new direction for the discovery and development of new, more useful therapeutic agents for metabolic disease.

Keywords: diabetes mellitus; insulin resistance; thiazolidinediones.

Publication types

  • Review

MeSH terms

  • Animals
  • Disease Models, Animal
  • Drosophila
  • Drug Discovery*
  • Humans
  • Insulin / metabolism
  • Insulin Resistance* / genetics
  • Insulin Secretion
  • Metabolic Diseases / drug therapy*
  • Metabolic Diseases / genetics
  • Metabolic Diseases / metabolism
  • Mice
  • Mice, Knockout
  • Mitochondria / drug effects*
  • Mitochondria / metabolism
  • Molecular Targeted Therapy*
  • Thiazolidinediones* / pharmacology


  • Insulin
  • Thiazolidinediones